Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it was targeting ...

Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of ...

CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering.

CAMP4 Therapeutics Corporation CAMP IPO will take place October, 11 on the NASDAQ exchange under the ticker CAMP. The company ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

Three US life-sciences companies have so far exceeded or met their goals in initial public offerings Thursday, showing ...

CeriBell (CBLL) and CAMP4 Therapeutics (CAMP) have set terms for their proposed initial public offerings. Read more here.

CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics ...

CAMP4 Therapeutics (NASDAQ:CAMP) priced its IPO of 6.82M shares at an initial public offering price of $11.00 per share. The gross proceeds are expected to be ~$75M. CAMP4’s common stock is expected ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...